Evidence map›Paper›PMID 39711218›Full record

ArticleHLA2024

Influence of HLA-G 3' Untranslated Region Haplotypes and SNP +3422 Gene Variants as Host Genetic Factors on the Outcomes of SARS-CoV-2 Infection During Acute and Post-Acute Phases in a German Cohort.

Hana Rohn, Fynn Elischer, Louisa Larbig, Sarah Jansen, Sabine Schramm, Mona Otte, Margarethe Konik, Krystallenia Paniskaki, Peter Weber, Johanna Reinold and 13 more

Abstract read
In one paragraph

Article in HLA, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

23 authors.

Hana RohnDepartment of Infectious Diseases, West German Centre for Infectious Diseases (WZI), University Hospital Essen, University Duisburg-Essen, Essen, Germany.
Fynn ElischerDepartment of Infectious Diseases, West German Centre for Infectious Diseases (WZI), University Hospital Essen, University Duisburg-Essen, Essen, Germany.
Louisa LarbigDepartment of Infectious Diseases, West German Centre for Infectious Diseases (WZI), University Hospital Essen, University Duisburg-Essen, Essen, Germany.
Sarah JansenDepartment of Infectious Diseases, West German Centre for Infectious Diseases (WZI), University Hospital Essen, University Duisburg-Essen, Essen, Germany.
Sabine SchrammInstitute for Transfusion Medicine, University Hospital Essen, University Duisburg-Essen, Essen, Germany.
Mona OtteDepartment of Infectious Diseases, West German Centre for Infectious Diseases (WZI), University Hospital Essen, University Duisburg-Essen, Essen, Germany.
Margarethe KonikDepartment of Infectious Diseases, West German Centre for Infectious Diseases (WZI), University Hospital Essen, University Duisburg-Essen, Essen, Germany.
Krystallenia PaniskakiDepartment of Infectious Diseases, West German Centre for Infectious Diseases (WZI), University Hospital Essen, University Duisburg-Essen, Essen, Germany.
Peter WeberDepartment of Infectious Diseases, West German Centre for Infectious Diseases (WZI), University Hospital Essen, University Duisburg-Essen, Essen, Germany.
Johanna ReinoldDepartment of Nephrology, University Hospital Essen, University Duisburg-Essen, Essen, Germany.
Anja GäcklerDepartment of Nephrology, University Hospital Essen, University Duisburg-Essen, Essen, Germany.
Adalbert KrawczykDepartment of Infectious Diseases, West German Centre for Infectious Diseases (WZI), University Hospital Essen, University Duisburg-Essen, Essen, Germany.
Benjamin WildeDepartment of Nephrology, University Hospital Essen, University Duisburg-Essen, Essen, Germany.
Mirko TrillingInstitute for Virology, University Hospital Essen, University Duisburg-Essen, Essen, Germany.
Rafael T MichitaDepartment of Medicine, Section of Infectious Diseases, Baylor College of Medicine, Houston, Texas, USA.
Birte MöhlendickInstitute of Pharmacogenetics, University Hospital Essen, University of Duisburg-Essen, Essen, Germany.
Winfried SiffertInstitute of Pharmacogenetics, University Hospital Essen, University of Duisburg-Essen, Essen, Germany.
Thorsten BrennerDepartment of Anesthesiology and Intensive Care Medicine, University Hospital Essen, University Duisburg-Essen, Essen, Germany.
Hannah DinseClinic for Psychosomatic Medicine and Psychotherapy, LVR-University Hospital Essen, University of Duisburg-Essen, Essen, Germany.
Eva M SkodaClinic for Psychosomatic Medicine and Psychotherapy, LVR-University Hospital Essen, University of Duisburg-Essen, Essen, Germany.
Peter A HornInstitute for Transfusion Medicine, University Hospital Essen, University Duisburg-Essen, Essen, Germany.
Oliver WitzkeDepartment of Infectious Diseases, West German Centre for Infectious Diseases (WZI), University Hospital Essen, University Duisburg-Essen, Essen, Germany.
Vera RebmannInstitute for Transfusion Medicine, University Hospital Essen, University Duisburg-Essen, Essen, Germany.

Funding

Deutsche Forschungsgemeinschaft DFG Projektnummer 422744262-TRR289Gilead Science GrantMinisterium für Kultur und Wissenschaft des Landes NRWRudolf Ackermann FoundationStiftung Universitätsmedizin Essen
6 · The paper itself

Abstract

HLA-G, an important immune-checkpoint (IC) molecule that exerts inhibitory signalling on immune effector cells, has been suggested to represent a key player in regulating the immune response to Severe Acute Respiratory Syndrome Coronavirus Type 2 (SARS-CoV-2). Since specific single-nucleotide polymorphisms (SNP) in the HLA-G 3'untranslated region (UTR), which arrange as haplotypes, are crucial for the regulation of HLA-G expression, we analysed the contribution of these genetic variants as host factors in SARS-CoV-2 infection during acute and post-acute phases. HLA-G gene polymorphisms in the 3'UTR were investigated by sequencing in an unvaccinated Coronavirus Disease 2019 (COVID-19) cohort during acute SARS-CoV-2 infection (N = 505) and in the post-acute phase (N = 253). The HLA-G 3'UTR haplotype known as UTR-3 (p = 0.002) and the variant rs17875408 (also known as +3422) T variant (p = 0.004) are independent prognostic risk factors for fatal COVID-19. The +3422T variant (p = 0.006) predicted also the early loss of neutralising SARS-CoV-2 antibodies. In addition, the HLA-G 3'UTR haplotype UTR-7 (p = 0.023) emerged as an independent prognostic factor for increased susceptibility to Long-COVID symptoms after SARS-CoV-2 infection. Our study highlights that due to the variability of the 3'UTR genetic background, HLA-G has the potential to contribute to the progression of SARS-CoV-2 infection, extending to the development of Long-COVID symptoms, despite the likely alterations in the microenvironment and associated HLA-G-specific regulatory elements over the course of the disease. By spotlighting HLA-G, the importance of the genetic background of IC and their pivotal role in modulating immune responses during and after COVID-19 are emphasised.

Indexed as

3' Untranslated RegionsCOVID-19HaplotypesHLA-G AntigensPolymorphism, Single NucleotideSARS-CoV-2AdultAgedCohort StudiesFemaleGenetic Predisposition to DiseaseGermanyHumansMaleMiddle AgedPrognosis3' Untranslated RegionsHLA-G AntigensCOVID‐19HLA‐GHLA‐G 3′UTRlong‐COVIDSARS‐CoV‐2

Identifiers

PMID39711218
PMCPMC11664307

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.